Tommaso Chini
University of Siena, Azienda Ospedaliera Universitaria Senese
Papers
3
Total Citations
12
H-Index
3
About
Tommaso Chini is a leading urological surgeon and researcher whose work focuses on advancing the surgical and pharmacological management of prostate cancer and its sequelae. His major contributions lie in optimizing post-prostatectomy outcomes, particularly through comparative effectiveness research on erectile dysfunction treatments. In a landmark 2019 prospective multicentre study, Chini directly compared the efficacy and safety of avanafil 200 mg versus sildenafil 100 mg after robot-assisted nerve-sparing prostatectomy, providing crucial evidence that second-generation phosphodiesterase type 5 inhibitors offer a valuable alternative with high selectivity. This work, cited 5 times, has informed clinical decision-making for post-surgical rehabilitation. Chini has also shed light on the complex, multidisciplinary management of urinary tract endometriosis (2022, 4 citations), highlighting his breadth in addressing silent, debilitating urological conditions. Furthermore, his analysis of over 1,500 patients in the MIRROR-SIU/LUNA and Pros-IT CNR studies (2020, 3 citations) documented how radical prostatectomy techniques have evolved in Italy over the past decade, offering a vital real-world benchmark for surgical trends. Through these contributions, Chini bridges surgical innovation with evidence-based pharmacological care, directly improving quality of life for men undergoing prostate cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3